CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia
Key facts
- Who runs it
- CorrectSequence Therapeutics Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Early phase 1
- People taking part
- 15 people, planned
- Started
- 15 Jun 2026
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 5 groups
- Treatments tested
- CS-121
- Record updated
- 18 June 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Male or female participants aged 18 years ≤ age < 65 years
- The serum triglyceride levels of the participants failed to be effectively controlled under the standard treatment regimen (or the medication that is available and tolerable as recommended by clinical practice) and were defined as having at least 3 records of different fasting triglyceride levels ≥ 5.65 mmol/L (500 mg/dL) within 2 years
- The screening period should include at least two different days with a TG level of ≥ 5.65 mmol/L (500 mg/dL), with an interval of at least 7 days
- Able to sign informed consent and comply with the requirements and restrictions specified in the informed consent form and the protocol
- Female participants must meet one of the following: be not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy/sterilization, or ≥1 year postmenopausal); or, if of childbearing potential, have a negative pregnancy test at screening and be willing to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) during the study. Male participants with reproductive potential must agree to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) throughout the entire post-dose observation period; males without reproductive potential must provide supporting medical history (e.g., post-vasectomy)
Who cannot take part
- Currently participating in other interventional clinical studies, or having an insufficient washout period of less than 5 half-lives or 30 days (whichever is longer) since the last administration of other investigational drugs
- Used antisense oligonucleotide (ASO)-based or small interfering RNA (siRNA)-based lipid-lowering drugs targeting APOC3 within 3 months prior to study drug administration
- Requires long-term use of systemic corticosteroids and steroid drugs and cannot discontinue the medication
- Patients who experienced acute pancreatitis within 4 weeks prior dosing
- History of acute coronary syndrome (ACS) within 6 months before dosing, such as myocardial infarction or unstable angina, or prior coronary revascularization (such as coronary artery bypass grafting), angioplasty or stent implantation
- In the investigator's judgment to be unsuitable for the study drug due to receipt of major surgery within 3 months before dosing
- Concomitant medications/treatments judged by the investigator to affect lipid metabolism, liver and kidney function, coagulation function, or interfere with the efficacy evaluation of the study drug
- Positive results for HBsAg, dual positivity for HCV antibody and RNA, positive for HIV, or positive for Treponema pallidum infection
- Known major organ diseases, mental disorders, Cushing's syndrome, hypothyroidism, history of lymphoproliferative disorders, or malignant tumors in any organ system, which are judged by the investigator as unsuitable for study participation due to potential intolerance to adverse events such as cytokine-Release-Storm
- Any of the following laboratory abnormalities at screening:
- ALT or AST ≥2 × ULN
- Total bilirubin ≥2 × ULN
- eGFR <30 mL/min/1.73 m²
- HbA1c ≥9%
- Absolute neutrophil count < 1.0 × 109/L
- Hemoglobin (female)< 100 g/L, Hemoglobin (male) < 110 g/L
- Platelet count < 100 × 109/L
- Coagulation function abnormalities judged by the investigator as unsuitable for CS-121 administration
- Patients of childbearing potential who are planning pregnancy, breastfeeding, or have fertility plans
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label, single-arm, dose-escalation IIT clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-65 years) with Severe Hypertriglyceridemia(sHTG).
The 5 groups in the trial
- Single Low Dose CS-121Treatment being tested
Participants in this arm will receive a single low dose (0.5mg/kg) of CS-121.
Treatment: CS-121
- Single Middle Dose CS-121Treatment being tested
Participants in this arm will receive a single middle dose (0.7mg/kg) of CS-121.
Treatment: CS-121
- Single High Dose CS-121Treatment being tested
Participants in this arm will receive a single high dose (1.0mg/kg) of CS-121
Treatment: CS-121
- Single selected Lower Dose 1 of CS-121Treatment being tested
Participants in this arm will receive a single selected lower dose 1 of CS-121.
Treatment: CS-121
- Single selected Lower Dose 2 of CS-121Treatment being tested
Participants in this arm will receive a single selected lower dose 2 of CS-121
Treatment: CS-121
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study to the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3 for the Treatment of Severe Hypertriglyceridemia in Adults
- Criteria questions
- Built from NCT07657780, who can take part
- Record updated
- 18 June 2026